Search results for "peripheral arterial disease"

showing 10 items of 74 documents

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the…

2004

Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD). Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lowe…

AdultMalemedicine.medical_specialtyPhthalic AcidsType 2 diabetesDiabeteGastroenterologyThromboxane A2Double-Blind MethodRisk FactorsInternal medicineDiabetes mellitusPeripheral arterial diseasemedicineRisk of mortalityHumansPicotamideCumulative incidenceGeneral NursingAgedPeripheral Vascular DiseasesAspirinAspirinbiologybusiness.industryAntiplatelet therapyantiplatelet therapy; aspirin; diabetes; peripheral arterial disease; picotamide; thromboxane synthase inhibitorsMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryThromboxane synthase inhibitors Indexed keywordsRelative riskbiology.proteinFemaleThromboxane-A synthasePicotamideCardiology and Cardiovascular MedicinebusinessDiabetic AngiopathiesPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugEuropean Heart Journal
researchProduct

Medicīna (Latvijas Universitātes Raksti; 812 sēj.)  

2016

Atbalsta vektora analīze:MEDICINE [Research Subject Categories]Ļaundabīgie audzējiMezenhimālās cilmes šūnasHronisks pankreatītsPeripheral arterial diseaseBiodegradējamie filleriKapoši sarkomaĀdas vēzisPsoriāzeS. epidermidis
researchProduct

Leukocyte–platelet aggregates—a phenotypic characterization of different stages of peripheral arterial disease

2016

The formation of monocyte-platelet aggregates and neutrophil-platelet aggregates (MPA and NPA, respectively) is influenced by inflammation, but also might contribute to an exacerbation of inflammatory responses in atherosclerotic plaque. The purpose of this study was to analyze MPA and NPA proportions in regard to different stages of peripheral arterial disease (PAD). Forty-five patients with intermittent claudication (IC) (3 groups: Rutherford (R)-1, R-2, and R-3; each n = 15), 20 patients with critical limb ischemia (CLI) (Rutherford 5 (40%) and 6 (60%)), and 20 healthy controls were studied. Analyses of monocyte (Mon) subpopulations (CD14++CD16- (classical) Mon1, CD14++CD16+ (intermediat…

Blood PlateletsMale0301 basic medicinemedicine.medical_specialtyNeutrophilsLipopolysaccharide ReceptorsInflammationComorbidity030204 cardiovascular system & hematologyFibrinogenMonocytesProinflammatory cytokinePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineLeukocytesmedicineHumansPlateletReceptors ImmunologicAgedCell AggregationWhole bloodAged 80 and overbusiness.industryMonocyteReceptors IgGHematologyGeneral MedicineCritical limb ischemiaMiddle AgedFlow CytometryIntermittent claudicationBlood Cell CountPhenotype030104 developmental biologyEndocrinologymedicine.anatomical_structureImmunologyFemalemedicine.symptombusinessCell Adhesion MoleculesBiomarkersmedicine.drugPlatelets
researchProduct

Polyvascular subclinical atherosclerosis in familial hypercholesterolemia: The role of cholesterol burden and gender

2019

International audience; BACKGROUND AND AIM:Heterozygous familial hypercholesterolemia (HeFH) is a genetic disease characterized by a heterogeneous phenotype. The assessment of cardiovascular (CV) risk is challenging for HeFH. Cholesterol burden (CB) allows to estimate the lifelong exposure to high levels of cholesterol. The aim of this study was to analyze the distribution of subclinical atherosclerosis and the relationship between atherosclerosis and the CB in a sample of HeFH patients, focusing on sex-related differences.METHODS AND RESULTS:154 asymptomatic HeFH subjects underwent coronary-artery-calcium score (CACs) and Doppler ultrasound of carotid and femoral arteries. Yearly lipid pro…

Carotid Artery DiseasesMaleCarotid atherosclerosisPeripheral arterial atherosclerosisTime Factors[SDV]Life Sciences [q-bio]Endocrinology Diabetes and MetabolismMedicine (miscellaneous)Coronary Artery DiseaseDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologySeverity of Illness Indexchemistry.chemical_compound0302 clinical medicineRisk FactorsAtherosclerosis; Calcium score; Cardiovascular disease; Cardiovascular risk; Cholesterol burden; Coronary artery calcium; Familial hypercholesterolemia; Peripheral arterial atherosclerosis; Adult; Aged; Asymptomatic Diseases; Biomarkers; Carotid Artery Diseases; Cholesterol; Coronary Artery Disease; Cross-Sectional Studies; Female; Femoral Artery; Genetic Predisposition to Disease; Humans; Hyperlipoproteinemia Type II; Male; Middle Aged; Paris; Peripheral Arterial Disease; Phenotype; Prevalence; Prognosis; Risk Assessment; Risk Factors; Severity of Illness Index; Sex Factors; Time Factors; Young AdultPrevalenceMedicineNutrition and Dietetics[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMiddle AgedPrognosisCardiovascular diseaseCalcium score3. Good healthFemoral ArteryCholesterol burdenCholesterolPhenotypeAtherosclerosiCardiologyPopulation studyFemalemedicine.symptomCardiology and Cardiovascular MedicineAdultParismedicine.medical_specialtyFamilial hypercholesterolemia030209 endocrinology & metabolismRisk AssessmentAsymptomaticCoronary artery calciumHigh cholesterolHyperlipoproteinemia Type IIPeripheral Arterial DiseaseYoung Adult03 medical and health sciencesSex Factors[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicineHumansGenetic Predisposition to DiseaseAgedbusiness.industryCholesterolAtherosclerosismedicine.diseaseCardiovascular riskCross-Sectional StudieschemistrySubclinical atherosclerosisAsymptomatic DiseasesbusinessBiomarkers
researchProduct

Consensus Document on Intermittent Claudication from the Central European Vascular Forum (C.E.V.F.)-3rd revision (2013) with the sharing of the Medit…

2014

This paper is the review of the Consensus Document on Intermittent Claudication of the Central European Vascular Forum (CEVF), published in 2008, and and shared with the North Africa and Middle East Chapter of International Union of Angiology and the Mediterranean League of Angiology and Vascular Surgery. The Document presents suggestions for general practitioners and vascular specialists for more precise and appropriate management of PAD, particularly of intermittent claudication, and underlines the investigations that should be required by GPs and what the GP should expect from the vascular specialist (angiologist, vascular surgeon). The idea of the Faculty is to produce a short document,…

ConsensusCritical IllnessGeneral Practiceintermittent claudicatioCardiovascular AgentsIntermittent ClaudicationSettore MED/11 - Malattie Dell'Apparato CardiovascolareSeverity of Illness IndexPeripheral Arterial DiseaseTreatment OutcomeIschemiaRisk FactorsAsymptomatic DiseasesHumansconsensus; intermittent claudicatio; peripheral arterial diseaseReferral and ConsultationRisk Reduction BehaviorVascular Surgical ProceduresIntermittent claudication peripheral arterial disease disease managementInternational angiology : a journal of the International Union of Angiology
researchProduct

Editor's Choice – Follow-up of Patients After Revascularisation for Peripheral Arterial Diseases: A Consensus Document From the European Society of C…

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Disease030204 cardiovascular system & hematology030230 surgeryPostoperative Complications0302 clinical medicineRestenosisRecurrenceSecondary Preventionfollow-upRandomized Controlled Trials as TopicUltrasonography Doppler Duplexmedicine.diagnostic_test3. Good healthEuropeSystematic reviewPractice Guidelines as TopicIN-STENT RESTENOSISCardiologyCardiology and Cardiovascular MedicineVascular Surgical ProceduresReoperationmedicine.medical_specialtyConsensusRevascularisationINFRAINGUINAL VEIN BYPASSMEDLINEPhysical examinationSTENOSIS03 medical and health sciencesrestenosisperipheral arterial diseaseInternal medicinemedicineHumansANGIOPLASTYVELOCITY CRITERIAbusiness.industryMagnetic resonance imagingNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENTRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness
researchProduct

Follow-up of patients after revascularisation for peripheral arterial diseases: a consensus document from the European Society of Cardiology Working …

2019

International audience; Peripheral arterial diseases comprise different clinical presentations, from cerebrovascular disease down to lower extremity artery disease, from subclinical to disabling symptoms and events. According to clinical presentation, the patient's general condition, anatomical location and extension of lesions, revascularisation may be needed in addition to best medical treatment. The 2017 European Society of Cardiology guidelines in collaboration with the European Society for Vascular Surgery have addressed the indications for revascularisation. While most cases are amenable to either endovascular or surgical revascularisation, maintaining long-term patency is often chall…

Epidemiologymedicine.medical_treatmentDiseaseFibromuscular dysplasia030204 cardiovascular system & hematology0302 clinical medicinefollow-up030212 general & internal medicineSocieties Medicalmedicine.diagnostic_test3. Good healthEuropeNatural historyTreatment OutcomeIN-STENT RESTENOSISCardiology030211 gastroenterology & hepatologyCardiology and Cardiovascular MedicineVascular Surgical Proceduresmedicine.medical_specialtyConsensusRevascularisationFIBROMUSCULAR DYSPLASIAINFRAINGUINAL VEIN BYPASSPhysical examinationRevascularizationSTENOSISrestenosis03 medical and health sciencesperipheral arterial diseaseInternal medicinemedicineHumansVELOCITY CRITERIAbusiness.industryNATURAL-HISTORYPerioperativeVascular surgery3126 Surgery anesthesiology intensive care radiologymedicine.diseaseStenosisDUPLEX ULTRASOUND SURVEILLANCEENDOVASCULAR TREATMENT3121 General medicine internal medicine and other clinical medicineRISK-FACTORSSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieCAROTID-ARTERYbusiness030217 neurology & neurosurgeryFollow-Up StudiesEuropean Journal of Preventive Cardiology
researchProduct

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Tri…

2021

Background: Patients with peripheral artery disease requiring lower extremity revascularization (LER) are at high risk of adverse limb and cardiovascular events. The VOYAGER PAD trial (Vascular Outcomes Study of ASA [Acetylsalicylic Acid] Along With Rivaroxaban in Endovascular or Surgical Limb Revascularization for PAD) demonstrated that rivaroxaban significantly reduced this risk. The efficacy and safety of rivaroxaban has not been described in patients who underwent surgical LER. Methods: The VOYAGER PAD trial randomized patients with peripheral artery disease after surgical and endovascular LER to rivaroxaban 2.5 mg twice daily plus aspirin or matching placebo plus aspirin and followed …

Lower extremity revascularizationMalemedicine.medical_specialtylower extremity revascularization; major adverse cardiovascular events (MACE); major adverse limb events (MALE); peripheral artery disease; revascularization; rivaroxaban.lower extremity revascularizationArterial diseasemedicine.medical_treatmentDiseaseRevascularizationperipheral artery diseasePeripheral Arterial DiseaseRivaroxabanPhysiology (medical)Internal medicinemedicineHumansIn patientmajor adverse cardiovascular events (MACE)major adverse limb events (MALE)AgedRivaroxabanAspirinAspirinbusiness.industryMiddle AgedCardiologyrevascularizationFemaleCardiology and Cardiovascular Medicinebusinessmedicine.drugSurgical revascularizationCirculation
researchProduct

Phenotypic characterisation of pro-inflammatory monocytes and dendritic cells in peripheral arterial disease

2012

SummaryAtherosclerosis is a chronic inflammatory process involving antigen-presenting cells like monocytes and dendritic cells (DC). The aim of this study was to perform a phenotypic characterisation of these cell types in patients with different degrees of peripheral arterial disease (PAD). Sixty patients with PAD [N= 30 intermittent claudication (IC), N= 30 critical limb ischemia (CLI)] and 30 controls were included. Peripheral blood leucocytes were analysed from peripheral blood by flow cytometry using different gating strategies to directly identify and analyse monocytes, myeloid DC, (mDC) and plasmacytoid DC (pDC). PAD patients showed a significantly higher proportion of proinflammator…

Male0301 basic medicineCD14Inflammation030204 cardiovascular system & hematologyCD16Peripheral blood mononuclear cellMonocytesImmunophenotypingProinflammatory cytokinePeripheral Arterial Disease03 medical and health sciences0302 clinical medicineIschemiamedicineHumansCD40 AntigensAgedAged 80 and overCD40biologybusiness.industryExtremitiesDendritic CellsHLA-DR AntigensHematologyCritical limb ischemiaIntermittent ClaudicationMiddle AgedIntermittent claudicationBlood Cell Countbody regions030104 developmental biologyCase-Control StudiesImmunologybiology.proteinFemaleB7-2 AntigenInflammation Mediatorsmedicine.symptombusinessThrombosis and Haemostasis
researchProduct

Obesity paradox in peripheral artery disease

2019

Background & aims: Previous studies have suggested an obesity survival paradox in patients with peripheral artery disease (PAD). We investigated the influence of obesity and underweight on adverse in-hospital outcomes in PAD. Methods: Patients diagnosed with PAD based on ICD-code I70.2 of the German nationwide database were stratified for obesity, underweight and a reference group with normal-weight/over-weight and compared regarding adverse in-hospital outcomes. Results: Between 01/2005-12/2015, 5,611,484 inpatients (64.8% males) were diagnosed with PAD; of those, 8.9% were coded with obesity and 0.3% with underweight. Obese patients were younger (70 (IQR 63/76) vs. 73 (66/80) years, P < 0…

Male0301 basic medicinemedicine.medical_specialtyArterial diseasemedicine.medical_treatment030209 endocrinology & metabolismDiseaseCritical Care and Intensive Care MedicineCohort StudiesPeripheral Arterial Disease03 medical and health sciences0302 clinical medicineThinnessGermanyInternal medicineHumansMedicineHospital MortalityObesityAged030109 nutrition & dieteticsNutrition and Dieteticsbusiness.industryCancerMiddle Agedmedicine.diseaseObesityAmputationFemaleUnderweightmedicine.symptombusinessLower mortalityObesity paradoxClinical Nutrition
researchProduct